

ExonHit's 2010 combined ordinary and extraordinary shareholders' meeting

- Shareholders adopted all resolutions proposed by ExonHit's Management Board

Paris, France – May 10, 2010 – At the combined ordinary and extraordinary shareholders' meeting held today with the necessary quorum, ExonHit's shareholders adopted all resolutions proposed by the Management Board.

Specifically, the shareholders have:

- approved both the parent company's and the group's consolidated financial statements for 2009;
- re-elected Laurent Condomine, Michel Picot and Deborah Smeltzer members of the Supervisory Board;
- renewed the authorization provided to the Management Board to set up a share buyback program designed as part of a liquidity agreement;
- renewed the financial authorizations given to the Management Board to raise capital.

An extraordinary shareholders' meeting will be convened in the near future to submit to the vote of ExonHit's shareholders resolutions allowing the closing of RedPath Integrated Pathology Inc. acquisition.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood based diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Corinne Hoff

+33 1 58 05 47 04

corinne.hoff@exonhit.com